There's a new player in the running game, and it's not the latest carbon-plated shoe or fancy GPS watch. GLP-1 medications ...

The 12-week human clinical trial began in early June 2024 and set out to investigate if, through these mechanisms of action, ...

In women with type 2 diabetes, use of GLP-1 receptor agonists was associated with a reduced risk of new-onset uterine ...

WHAT TO KNOW ABOUT GLP-1 SHORTAGES ... than 1 million deaths each year and contributes to nearly 5 million, a toll that’s expected to grow in the next 25 years without global action.

GLP-1 agonists are a class of medications that mimic the action of the hormone GLP-1 (glucagon-like peptide-1), which is involved in insulin production and appetite regulation. “GLP-1 stands for ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

Results from a retrospective cohort study show lower all-cause mortality and fewer hospitalizations and intestinal ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

The FDA said it does not plan to take action against GLP-1 compounders for certain violations while it re-evaluates Eli Lilly’s (LLY) Zepbound drug, Endpoints News’ Nicole DeFeudis reports.

Medicines affecting the GLP-1 receptor are in vogue for weight ... the weight loss market but are loath to invest in the mechanism of action favored by the biggest players, taking a look at ...

LifeVantage (LFVN) announced results from a human clinical trial performed on the new MindBody GLP-1 System. Results from the trial included a ...

Ω* The 12-week human clinical trial began in early June 2024 and set out to investigate if, through these mechanisms of action, the MindBody GLP-1 System could holistically and sustainably ...